课题基金 / 基金详情

Role of BAZ2A in MLL-r leukemia and therapeutic response

Role of BAZ2A in MLL-r leukemia and therapeutic response
BAZ2A 在 MLL-r 白血病中的作用和治疗反应
批准号:
10593927
负责人:
Chun-Wei David Chen
金额:
$38.78万
依托单位国家:
美国
项目类别:
财政年份:
2019
资助国家:
美国
项目状态:
已结题
起止时间:
2019-04-01 至 2024-03-31

项目摘要

项目成果

Chun-Wei David Chen的其他基金

相似基金

相关文献

中文摘要
翻译
项目总结/摘要 MLL重排(MLL-r)白血病占人类急性白血病的5-10%,并且与 预后不良。未满足的临床需求和缺乏有效的MLL-r靶向治疗 白血病强调需要新的治疗方案。最近的癌症表观遗传学研究发现, 组蛋白H3赖氨酸79(H3 K79)甲基转移酶DOT 1 L在MLL-r白血病发生中的中心作用。 已经注意到DOT 1 L抑制剂作为单一药剂治疗的重要临床应答,然而, 预计联合治疗是必要的。 我们基于MLL-r白血病中DOT 1 L抑制剂致敏筛选的初步研究已经确定 BAZ 2A的抑制显著增加DOT 1 L抑制剂的抗白血病活性。客观 本申请的目的是确定介导SIRT 1可用性的关键表观遗传机制, 抑制MLL-r白血病癌基因表达。我们的中心假设是BAZ 2A,一种染色质, 重塑蛋白的rDNA基因座,介导SIRT 1的重新分配,组蛋白去乙酰化和沉默, MLL-r/DOT 1 L驱动的癌基因。我们将剖析BAZ 2A/SIRT 1染色质靶向机制(目的1), 研究DOT 1 L和BAZ 2A联合治疗的疗效(目标2),并验证一种新的饱和度 CRISPR蛋白质扫描技术用于DOT 1 L和BAZ 2A中功能元件的从头发现 (Aim 3)。 这项研究是创新的,因为(1)它引入了同时靶向多个 组成部分的表观遗传网络,以有效地抑制癌症程序,(2)它建立了一个 全新的基因筛选方法,用于亚蛋白水平的功能结构域发现。这样做的影响 研究将具有重要意义,因为(1)它立即提供了新的治疗机会 针对难以治疗的MLL-r白血病,和(2)它将有助于确定新的功能元件, 表观遗传调节剂用于未来的药物靶向。
英文摘要
PROJECT SUMMARY/ABSTRACT MLL-rearranged (MLL-r) leukemias account for 5-10% of human acute leukemia and is associated with poor prognosis. The unmet clinical needs and the lack of an effective targeted therapy to the MLL-r leukemias emphasize the need for novel regimens. Recent cancer epigenetics studies discovered a central role for the histone H3 lysine 79 (H3K79) methyltransferase DOT1L in MLL-r leukemogenesis. Important clinical responses have been noted with DOT1L inhibitor treatment as a single agent, however, it is expected that combination treatments will be necessary. Our preliminary studies based on a DOT1L-inhibitor sensitization screen in MLL-r leukemia have identified suppression of BAZ2A significantly increases the anti-leukemic activity of the DOT1L inhibitor. The objective of this application is to determine the critical epigenetic mechanisms that mediate the availability of SIRT1 to suppress oncogene expression in MLL-r leukemia. Our central hypothesis is that BAZ2A, a chromatin remodeling protein of rDNA loci, mediates redistribution of SIRT1 for histone deacetylation and silencing of MLL-r/DOT1L-driven oncogene. We will dissect the BAZ2A/SIRT1 chromatin targeting mechanisms (Aim 1), investigate the efficacy of DOT1L and BAZ2A combination therapies (Aim 2), and validate a novel saturation CRISPR protein scan technology for de novo discovery of the functional elements in DOT1L and BAZ2A (Aim 3). This study is innovative because (1) it introduces a novel concept of simultaneously targeting multiple components of an epigenetic network to efficiently suppress the cancer programs, and (2) it establishes a brand new genetic screen approach for a sub-protein level functional domain discovery. The impact of this research will be of significance because (1) it immediately provides novel therapeutic opportunities against the difficult-to-treat MLL-r leukemias, and (2) it will help identify novel functional elements in epigenetic regulators for future pharmaceutical targeting.
期刊论文(1)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1126/sciadv.adc8911
发表时间: 2022-12-23
期刊: Science advances
影响因子: 13.6
作者: []
通讯作者:
Mechanism and therapeutic opportunities of targeting the Tudor domain
Integrative Analyses of Saturation CRISPR Protein Scan
Role of BAZ2A in MLL-r leukemia and therapeutic response
Combinational targeting the feed forward epigenetic circuitry in mixed lineage leukemia
海外基金